Sidedness and TP53 Mutations Impact OS in Anti-Egfr but Not Anti-Vegf Treated mCRC - An Analysis of the KRAS Registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie)

BMC Cancer - United Kingdom
doi 10.1186/s12885-017-3955-4
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Emergence of KRAS Mutations and Acquired Resistance to Anti-Egfr Therapy in Colorectal Cancer

Nature
Multidisciplinary
2012English

Rationale Medikamentöse Tumortherapie

Der Urologe
Urology
2013English

Predicting Efficacy and Toxicity in the Era of Targeted Therapy: Focus on Anti-Egfr and Anti-Vegf Molecules

Current Drug Metabolism
Clinical BiochemistryPharmacology
2011English

Impact of TP53 Mutations on Outcome in EGFR -Mutated Patients Treated With First-Line Tyrosine Kinase Inhibitors

Clinical Cancer Research
Cancer ResearchOncology
2016English

First-Line Treatment in NSCLC Harboring EGFR Common Mutations: EGFR TKI in Monotherapy or in Combination With Anti-Vegf?

Expert Review of Anticancer Therapy
OncologyPharmacology
2016English

Difficult but Not Impossible: In Search of an Anti-Candida Vaccine

Current Tropical Medicine Reports
Infectious DiseasesAllergyImmunology
2019English

EGFR Status in Mesothelioma: Possible Implications for the Efficacy of Anti-Egfr and Anti-Met Therapies

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2016English

Anti-Vegf Therapies in the Clinic

Cold Spring Harbor perspectives in medicine
BiochemistryMedicineGeneticsMolecular Biology
2012English

Skin Toxicity Ant Anti-Egfr-Therapy: A Mock Trouble for Elderly and Frail Patients With McRc

Annals of Hematology & Oncology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy